Where Will Lexicon Pharmaceuticals Inc (LXRX) Stock Go Next After It Has Fallen 16.42% in a Week?

Lexicon Pharmaceuticals Inc (LXRX) stock is down 16.42% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Lexicon Pharmaceuticals Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on LXRX!

See Full LXRX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With LXRX Stock Today?

Lexicon Pharmaceuticals Inc (LXRX) stock has fallen -10.65% while the S&P 500 is up 0.17% as of 9:34 AM on Wednesday, Nov 8. LXRX is down -$0.13 from the previous closing price of $1.25 on volume of 149,395 shares. Over the past year the S&P 500 has gained 15.21% while LXRX is down -47.42%. LXRX lost -$0.68 per share in the over the last 12 months. To screen for more stocks like Lexicon Pharmaceuticals Inc click here.

More About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Click Here to get the full Stock Report for Lexicon Pharmaceuticals Inc stock.